Afficher la notice abrégée

Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHURIN, Nicolas
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorROUYER, Magali
dc.contributor.authorGROSS-GOUPIL, M.
dc.contributor.authorREBILLARD, X.
dc.contributor.authorSOULIÉ, M.
dc.contributor.authorHAASER, T.
dc.contributor.authorROUMIGUIÉ, M.
dc.contributor.authorLE MOULEC, S.
dc.contributor.authorCAPONE, C.
dc.contributor.authorPIERRÈS, M.
dc.contributor.authorLAMARQUE, S.
dc.contributor.authorJOVÉ, J.
dc.contributor.authorBIGNON, E.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDROZ-PERROTEAU, Cécile
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOORE, Nicholas
dc.contributor.authorBLIN, Patrick
dc.date.accessioned2021-02-19T09:41:14Z
dc.date.available2021-02-19T09:41:14Z
dc.date.issued2020
dc.identifier.issn1877-7821en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26294
dc.description.abstractEnBackground There is a lack of information about the burden of metastatic castration-resistant prostate cancer (mCRPC). The present work aims to estimate the incidence and prevalence of mCRPC in 2014 using the French nationwide healthcare database (SNDS). Methods Prevalence and incidence were estimated based on an SNDS extraction of men covered by the general healthcare insurance (86 % of the French population), and aged ≥40. Patients with mCRPC were identified amongst prostate cancer cases using an algorithm estimating a date of first metastasis management and a date of castration resistance. This algorithm was validated by clinical experts through a blind review of 200 anonymized medical charts from SNDS data. Prevalence and incidence were standardized on the European Standard Population (2013 edition). Results Prevalence and incidence of mCRPC were estimated as, respectively, 62 and 21 cases per 100 000 men in 2014. Less than one mCRPC case per 100 000 was observed in men aged 40–49. Maximum mCRPC incidence was in men aged 80–89 (175 per 100 000). The algorithm used for mCRPC identification had 97 % positive and 99 % negative predictive values. Conclusion The good performances of the algorithm for mCRPC identification and the consistency of the generated results with the existing data highlight the robustness of these first estimates of mCRPC prevalence and incidence. Future updates will call for algorithm adjustment as practices evolve over time. These first real-life data will serve for future follow-up of the impact of changes in the management of prostate cancer.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectPharmacoEpi-Drugs
dc.title.enEpidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database
dc.title.alternativeCancer Epidemiolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.canep.2020.101833en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33068878en_US
bordeaux.journalCancer Epidemiologyen_US
bordeaux.page101833en_US
bordeaux.volume69en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cancer%20Epidemiology&rft.date=2020&rft.volume=69&rft.spage=101833&rft.epage=101833&rft.eissn=1877-7821&rft.issn=1877-7821&rft.au=THURIN,%20Nicolas&ROUYER,%20Magali&GROSS-GOUPIL,%20M.&REBILLARD,%20X.&SOULI%C3%89,%20M.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_CE_2020_Thurin.pdf
Taille:
1.333Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée